Tetra Bio-Pharma (TSXV:TBP) shares update on the clinical trial for PPP005 cannabis oil-based capsules.

As quoted in the press release:

Tetra and its clinical research partner, Santé Cannabis, announced that the clinical trial in non-cancer chronic pain patients will be completed later this autumn as promised.  This was the first clinical trial of its kind in evaluating the safety and efficacy of different doses and ratios of cannabis oils versus placebo. The study included a dose titration phase (gradually bringing patients to the required dose) allowing us to better understand the side effect profile of the oils as well as the development of tolerance to these effects. Thus far, no other company in the medical cannabis space has undertaken such an exhaustive study to understand the therapeutic benefits and side effects of a cannabis oil-based capsule.

Dr. Chamberland, interim CEO and CSO added, “We continue to deliver on our business model that provides for evidence-based research to support the usage of cannabis-derived products and provide the medical community with the data they have been demanding from this sector. The trial has already provided unique valuable clinical data on both safe and efficacious dose levels of CBD and THC-CBD oils. This data will allow Tetra to advance to the next phase of product development wherein the company is developing products for its commercial partner Genacol Corporation Canada, as well as food supplements for the retail market and finally, our capsules that we intend to use in the treatment of chronic and cancer related pain.  Tetra has already established itself as a trailblazer in the natural health product segment with the announcement of our intention to launch a Hemp Energy Drink and we intend to build on that momentum.”

Click here to read the full press release.

Source: globenewswire.com

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”) , a leading international provider of consumer products in cannabis, today reported its financial and operating results for the first quarter ended March 31, 2021 . All financial information is provided in U.S. dollars unless otherwise indicated.

1Q 2021 Financial Highlights (Unaudited)

Keep reading... Show less

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Harvest Health & Recreation Inc. (“Harvest” or the “Company”) (OTC: HRVSF) in connection with the proposed acquisition of the Company by Trulieve Cannabis Corp. (“Trulieve”) (OTC: TCNNF). Under the terms of the merger agreement, Harvest shareholders will receive 0.1170 shares of Trulieve common stock for each Harvest share that they own, representing implied per-share merger consideration of approximately $4.79 based upon Trulieve’s May 7, 2021 closing price of $40.92 . Upon consummation of the transaction, current Harvest shareholders will own only 26.7% of the issued and outstanding pro forma Trulieve shares.

Keep reading... Show less

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Executive Chairman, will speak at Canaccord Genuity’s 5th Annual Global Cannabis Conference on Tuesday, May 11, 2021 at 2:30 p.m. EDT.

Participants may access a live webcast of the presentation by going to the Upcoming Events page at thecronosgroup.com . A replay will be made available shortly following the live presentation.

Keep reading... Show less

Numinus and Multidisciplinary Association for Psychedelic Studies collaboration
will conduct follow-on Compassionate Access trial in real-world setting in Vancouver, Canada

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today congratulates the Multidisciplinary Association for Psychedelic Studies (MAPS) and the MAPP1 trial study team for their announcement of results from the Phase 3 randomized clinical trial of MDMA-assisted therapy for the treatment of severe post-traumatic stress disorder (PTSD).

Keep reading... Show less

Combined Company Will Maintain Industry Leading Scale in Retail, Cultivation & Production

Footprint Provides National Scale with a Deep Regional Focus in Attractive Markets

Keep reading... Show less